Format

Send to

Choose Destination
Neurotherapeutics. 2013 Jul;10(3):391-9. doi: 10.1007/s13311-013-0182-9.

α-Synuclein and mitochondria: partners in crime?

Author information

1
Gladstone Institute of Neurological Disease, 1650 Owens Street, San Francisco, CA 94158, USA. ken.nakamura@ucsf.edu

Abstract

Increased α-synuclein levels and mutations in mitochondria-associated proteins both cause familial Parkinson's disease (PD), and synuclein and mitochondria also play central, but poorly understood, roles in the pathogenesis of idiopathic PD. A fraction of synuclein interacts with mitochondria, and synuclein can produce mitochondrial fragmentation and impair mitochondrial complex I activity. However, the consequences of these mitochondrial changes for bioenergetic and other mitochondrial functions remain poorly defined, as does the role of synuclein-mitochondria interactions in the normal and pathologic effects of synuclein. Understanding the functional consequences of synuclein's interactions with mitochondria is likely to provide important insights into disease pathophysiology, and may also reveal therapeutic strategies.

PMID:
23512373
PMCID:
PMC3701775
DOI:
10.1007/s13311-013-0182-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center